Skip to main content

Navigation group

Type at least 3 characters
2,923 articles

Articles

Study Protocol

Published on 13 Feb 2023

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial

in Molecular and Cellular Oncology

  • Giulia Martini
  • Davide Ciardiello
  • Stefania Napolitano
  • Erika Martinelli
  • Teresa Troiani
  • Tiziana Pia Latiano
  • Antonio Avallone
  • Nicola Normanno
  • Massimo Di Maio
  • Evaristo Maiello
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
Frontiers in Oncology
doi 10.3389/fonc.2023.1069370
  • 2,709 views
  • 10 citations